CA
NZ
UK
AU
IND
US
AbCelleraBiologicshas entered a new material agreement that widens access to its antibody discovery platform, offering investors upside through broader collaboration possibilities. The deal enhances the company’s capacity to partner with pharmaceutical firms and accelerate pipeline development.
Lexaria Bioscience (NASDAQ:LEXX) shares are pulling back modestly in pre-market trading, giving back a small piece of Thursday's sharp 32.35% rally that followed the announcement of a new partnership. The Kelowna, Canada-based company is a drug delivery innovator known for its patented DehydraTECH technology, …
MapLight Therapeutics (NASDAQ:MPLT) shares are climbing in pre-market trading after the clinical-stage biopharmaceutical company reported positive Phase 2 results and provided aBusinessupdate alongside its second-quarter earnings. MapLight is a Redwood City, California-based company focused on developing circuit-specific therapies for central nervous system disorders including …
Valneva SE (NASDAQ:VALN) shares are surging in pre-market trading after theEuropean Medicines Agency (EMA)validated the Marketing Authorization Application (MAA) for PF-07307405, the company's 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate developed inPartnershipwith Pfizer. Validation means the EMA has accepted the application …
Zentalis Pharmaceuticals (NASDAQ:ZNTL) shares are trading lower in pre-market trading after the clinical-stage oncology company announced the pricing of a dilutive share offering. The San Diego-based company is a clinical oncology innovator advancing late-stage development of azenosertib, an investigational, potentially first-in-class WEE1 inhibitor being …
If you're watching Zoetis (NYSE:ZTS), the stock is essentially holding steady in pre-market trading as the market weighs a new positive regulatory catalyst against broader concerns about softening U.S. companion-animal demand. The FDA has authorized Simparica Trio, already the first product approved to provide …
Eton Pharmaceuticals (NASDAQ:ETON) shares are surging in pre-market trading, up roughly 23% to around $50, after the company reportedBlowoutsecond-quarter 2026 results driven by the HEMANGEOL relaunch and broad rare-disease portfolio growth. Revenue nearly doubled year-over-year to $37.6 million, topping the $27.1 million consensus, while …
Boston Scientific (NYSE:BSX) shares are climbing in pre-market trading, building on a recovery that began after a sharp selloff earlier this year triggered by a cut to full-year 2026 organic growth guidance. The rally is being reinforced by notable insider buying: CEO Michael F. …
● Tenon Medical posted record second-quarter revenue, its strongest quarterly sales performance to date.
● Curis priced a $5.6 million raise carrying an explicit going-concern warning, underscoring the company's thin financial cushion.
Please wait processing your request...